Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia   WALTHAM, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet...

Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22 WALTHAM, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system...

Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates Four late-stage trials underway, targeting schizophrenia, major depressive disorder and insomnia disorder Planning for commercialization moves forward  Management to host conference call today at...

Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia Multi-center, international trial targets significant unmet need for which no treatments are approved Approximately 500 patients to be enrolled at 60 clinical sites in U.S. and Europe WALTHAM,...

Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia WALTHAM, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...